Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Melatonin on Depression, Anxiety, Cognitive Function and Sleep Disturbances in Breast Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women, age 30-75, with breast cancer who are admitted for a lumpectomy or mastectomy at Herlev Hospital~* ASA score I-III~* No sign of depression measured my Major Depression Inventory (MDI)~* Not pregnant~Exclusion Criteria:~* Neoadjuvant chemotherapy~* Treatment with SSRI, Warfarin or other anticoagulants (except 75 mg ASA daily), MAO inhibitors or calcium blockers~* Rotor or Dubin-Johnson syndrome~* Epilepsy~* Known allergic reaction to melatonin~* Known and treated sleep apnea~* Diabetes Mellitus - insulin treated~* Ongoing or previous medically treated depression or bipolar disorder~* Known autoimmune diseases - systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and sclerose~* Incompensated liver cirrhosis~* Severe kidney disease~* Previous or current cancer~* Known medically treated sleep-disorder (insomnia, restless legs etc)~* Shift-work and night-work~* Daily alcohol intake of more than 5 units~* Pre-operative treatment with psychopharmacological drugs, opioids or anxiolytics (including all sleeping pills)~* Predicted bad compliance~* Pregnant or breast-feeding~* Pre-operative Mini Mental State Evaluation (MMSE) score less than 24

- Gender: FEMALE
- Minimum Age: 30 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Melatonin (Type: ACTIVE_COMPARATOR): 6 mg oral melatonin daily
- Placebo (Type: PLACEBO_COMPARATOR): 6 mg oral placebo daily

Based on this trial design, predict the completion outcome and termination type (if applicable).